So erreichen Sie uns:

Gebührenfreie Rufnummer

Österreich, Tschechien, Frankreich, Deutschland, Italien, Polen, Spanien, Schweiz, Türkei und Großbritannien
+ 800 624 367 23
+ 800 MAGFORCE
Vereinigte Staaten, Kanada, Guam, Puerto Rico und US-Jungferninseln
+ 1 844 833 9623
Rufnummern weitere Länder
Nachricht schreiben
How to reach us:

Toll-free phone number

Austria, Czech Republic, France, Germany, Italy, Poland, Spain, Switzerland, Turkey and Great Britain
+ 800 624 367 23
+ 800 MAGFORCE
United States, Canada, Guam, Puerto Rico and US Virgin Islands
+ 1 844 833 9623
Phone numbers for other countries
Write a message

Patient case report on the use of NanoTherm® therapy for the treatment of progressive glioblastoma

Course of disease in a 47-year-old patient

Diagnosis

On August 17, 2007, a left temporo-occipital glioblastoma was diagnosed in a 47-year-old patient and confirmed on August 24, 2007 by a stereotactically sampled biopsy. Despite the adjacent radiotherapy (1.8 Gy/d; total dose 59 Gy) with concomitant administration of Temozolomide (from September 10 – October 26, 2007) followed by three cycles of Temozolomide (November 30 – February 5, 2008) the tumor clearly continued to grow.

Decision for NanoTherm® Therapy

The tumor volume was 23.7 ml on February 19, 2008, and it was decided to treat the patient with a nanoparticle-mediated thermotherapy simultaneously with radiotherapy.

Therapy

  • Instillation of 4.7 ml of NanoTherm® on March 12, 2008
  • Postoperative CT on March 13, 2008
  • Treatment of patient with alternating magnetic field in the NanoActivator® (March 18 - April 4, 2008: twice a week for 1 hour over a period of 3 weeks, 6 sessions in total)

Side effects

During the NanoTherm® therapy the patient did not complain of any side effects.

Results

  • CT follow-up scans were performed at 3, 6, 8, 11, and 15 months following completion of the NanoTherm® Therapy
  • No tumor progression could be diagnosed
  • After 18 months, the status of the patient deteriorated rapidly
  • The patient passed in September 2009 due to tumor progression (18 months)

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors. NanoTherm® therapy is currently available to national and foreign patients in dedicated hospitals in Germany.

Contact

For more information, please contact our Patient Services under T: +49 30 - 30 83 80 - 73 (free call within Germany: 0800 - 66 46 46 1) or ask your physician. You can also write us at